Last reviewed · How we verify

Evening primrose oil(EPO)

Ain Shams University · Phase 3 active Small molecule

Evening primrose oil provides gamma-linolenic acid (GLA), a polyunsaturated fatty acid that is converted to anti-inflammatory metabolites, primarily dihomo-gamma-linolenic acid (DGLA) and arachidonic acid derivatives.

Evening primrose oil provides gamma-linolenic acid (GLA), a polyunsaturated fatty acid that is converted to anti-inflammatory metabolites, primarily dihomo-gamma-linolenic acid (DGLA) and arachidonic acid derivatives. Used for Rheumatoid arthritis (Phase 3), Inflammatory joint disease.

At a glance

Generic nameEvening primrose oil(EPO)
SponsorAin Shams University
Drug classBotanical/Nutraceutical supplement; omega-6 polyunsaturated fatty acid source
ModalitySmall molecule
Therapeutic areaRheumatology; Immunology; Inflammatory disorders
PhasePhase 3

Mechanism of action

EPO is rich in omega-6 polyunsaturated fatty acids, particularly GLA. Once ingested, GLA is metabolized to DGLA and downstream eicosanoids that compete with pro-inflammatory arachidonic acid metabolites, thereby reducing inflammatory cytokine production and modulating immune responses. This mechanism is thought to reduce joint inflammation, pain, and disease progression in inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: